{"id":3017,"date":"2016-07-25T16:20:48","date_gmt":"2016-07-25T16:20:48","guid":{"rendered":"http:\/\/www.medicalmarijuanainc.com\/?p=16614"},"modified":"2016-07-25T16:20:48","modified_gmt":"2016-07-25T16:20:48","slug":"forbes-features-medical-marijuana-inc-portfolio-company-kannalife-article-nfl-concussion-related-disease-cte","status":"publish","type":"post","link":"https:\/\/medicalmarijuanainc.com\/2016\/07\/25\/forbes-features-medical-marijuana-inc-portfolio-company-kannalife-article-nfl-concussion-related-disease-cte\/","title":{"rendered":"Forbes Features Medical Marijuana, Inc. Portfolio Company Kannalife In Article On NFL and Concussion-Related Disease CTE"},"content":{"rendered":"
Article Explains How Cannabis Could Be the \u201cHoly Grail\u201d of Neurological Medicine<\/i><\/b><\/p>\n
San Diego, CA \u2013 July 25, 2016<\/b> \u2013 <\/span>Medical Marijuana, Inc.<\/span><\/a> (OTC: MJNA) announced today that its portfolio company <\/span>Kannalife Sciences, Inc.<\/span><\/a> (\u201cKannalife\u201d) was the focus of a <\/span>Forbes article<\/span> that discussed the Kannalife\u2019s role in developing a pharmaceutical treatment for the degenerative brain disorder Chronic Traumatic Encephalopathy (CTE), a concussion-related disease that is pervasive among NFL players.<\/span><\/p>\n The July 22 <\/span>Forbes<\/span> article titled, \u201d<\/span>NFL To Name New Medical Chief, Bringing Hope for Cannabis Concussion Treatment<\/span>,\u201d describes how <\/span>bio-pharmaceutical and phyto-medical<\/span> company <\/span>Kannalife<\/span><\/a> is conducting U.S. government-licensed research to determine the effects of cannabinoids on CTE and how such research could lead to major changes in how the NFL treats and prevents players\u2019 brain injuries. The article also includes success stories from former NFL players who have used medical marijuana instead of addictive opioid painkillers to address their brain injury-related symptoms.<\/span><\/p>\n In the article, <\/span>Kannalife<\/span><\/a> co-founder Thoma Kikis cites the plethora of athletes, including girls\u2019 soccer players, which could benefit from<\/span> Kannalife\u2019s<\/span><\/a> research. \u201cWe want to be able to have a pharmaceutical product that\u2019s available the moment an injury happens,\u201d Kikis told Forbes. \u201cIt would be great if the parents know what they\u2019re giving their children. That it\u2019s provided by a doctor and not from a dispensary.\u201d<\/span><\/p>\n Scientific research studies<\/span><\/a> have found that <\/span>cannabidiol (CBD)<\/span> reduces brain swelling and neurological impairment following a traumatic brain injury, which in turn improves recovery. <\/span>Kannalife<\/span><\/a> currently holds two licenses with the U.S. National Institutes of Health for U.S. Patent 6,630,507 <\/span>\u201cCannabinoids as Antioxidants and Neuroprotectants.\u201d<\/span> These licenses are currently in use by Kannalife to develop novel therapeutic drugs to treat CTE and hepatic encephalopathy (HE). While CBD from marijuana is tightly restricted, CBD found naturally in hemp is legal throughout all 50 states in the U.S.<\/span><\/p>\n \u201cCTE can affect everybody from children who fall off their bikes, to combat veterans, to the professional NFL football players that were highlighted in this Forbes article,\u201d said <\/span><\/p>\n Medical Marijuana, Inc. CEO Dr. Stuart Titus.<\/span><\/p>\n \u201cEach time a story is written on the positive effects of cannabinoid therapeutics, hemp and marijuana \u2013 as well as cannabis derivatives such as CBD \u2013 we are one step closer to \u2018access for all\u2019 to this powerful botantical and its chemistry,\u201d added Dr. Titus. \u201cWe are grateful for news organizations that continue spreading the word about the medical benefits of cannabis, which has the potential to effectively treat or prevent CTE, and for our<\/span> Kannalife<\/span><\/a> researchers who are on the front lines developing cannabinoid-based therapeutics and solutions.\u201d<\/span><\/p>\n ###<\/span><\/p>\n About Kannalife Sciences, Inc.<\/i><\/b><\/p>\n Kannalife Sciences, Inc. is a phyto-medical company involved in the research and development of novel therapeutic agents designed to be neuroprotectants and immuno-modulators. Kannalife is currently conducting research and development at the Pennsylvania Biotechnology Center in Doylestown, PA, for target drug candidates to treat Hepatic Encephalopathy (“HE”) and Chronic Traumatic Encephalopathy (“CTE”). HE and CTE are oxidative stress related diseases that affect cognitive and behavioral functions. For more information, visit:\u00a0<\/span>www.Kannalife.com<\/span><\/a>.<\/span><\/p>\n About Medical Marijuana, Inc.<\/b><\/p>\n Our mission is to be the premier cannabis and hemp industry innovators, leveraging our\u00a0team of professionals to source, evaluate and purchase value-added companies and\u00a0products, while allowing them to keep their integrity and entrepreneurial spirit. We strive\u00a0to create awareness within our industry, develop environmentally-friendly, economically\u00a0sustainable businesses, while increasing shareholder value. For details on\u00a0Medical\u00a0Marijuana, Inc.\u2019s portfolio and investment companies, visit\u00a0<\/span>www.medicalmarijuanainc.com<\/span><\/a>.<\/span><\/p>\n \u2028<\/span>To see Medical Marijuana, Inc.\u2019s video statement,\u00a0<\/span>click here<\/span><\/a>.\u00a0Shareholders are also encouraged to visit the\u00a0<\/span>Medical Marijuana, Inc. Shop<\/span><\/a>\u00a0for\u00a0discounted products.<\/span><\/p>\n FORWARD-LOOKING DISCLAIMER<\/i><\/b><\/p>\n This press release may contain certain forward-looking statements and information, as\u00a0defined within the meaning of Section 27A of the Securities Act of 1933 and Section\u00a021E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created\u00a0by those sections. This material contains statements about expected future events\u00a0and\/or financial results that are forward-looking in nature and subject to risks and\u00a0uncertainties. Such forward-looking statements by definition involve risks, uncertainties\u00a0and other factors, which may cause the actual results, performance or achievements of\u00a0Medical Marijuana, Inc. to be materially different from the statements made herein.<\/span><\/i><\/p>\n FOOD AND DRUG ADMINISTRATION (FDA) DISCLOSURE<\/i><\/b><\/p>\n These statements have not been evaluated by the FDA and are not intended to\u00a0diagnose, treat or cure any disease.<\/span><\/i><\/p>\n LEGAL DISCLOSURE<\/i><\/b><\/p>\n Medical Marijuana Inc. does not sell or distribute any products that are in violation of the\u00a0United States Controlled Substances Act (US.CSA). These companies do grow, sell, and distribute hemp-based products and are involved with the federally legal distribution\u00a0of medical marijuana-based products within certain international markets. Cannabidiol is\u00a0a natural constituent of hemp oil.<\/span><\/i><\/p>\n \u00a0<\/b><\/p>\n Public Relations Contact:<\/b><\/p>\n Andrew Hard<\/span><\/p>\n Chief Executive Officer<\/span><\/p>\n CMW Media<\/span><\/p>\n andrew.hard@cmwmedia.com<\/span><\/a><\/p>\n www.cmwmedia.com<\/span><\/a><\/p>\n \u00a0<\/span><\/p>\n Corporate Business Contact:<\/b><\/p>\n Nicholas R. Massalas<\/span><\/p>\n Director of Business Development<\/span><\/p>\n Medical Marijuana, Inc.<\/span><\/p>\n OTC Symbol: MJNA<\/span><\/p>\n Toll Free: 888-OTC- MJNA\u00a0<\/span>(888-682- 6562<\/span><\/a>)<\/span><\/p>\n www.medicalmarijuanainc.com<\/span><\/a><\/p>\n www.facebook.com\/mjnainc<\/span><\/a><\/p>\n \u00a0<\/span><\/p>\n Investor Relations Contact:<\/b><\/p>\n EquiNet, LLC<\/span><\/p>\n Toll Free:\u00a0<\/span>(877) 964.6463<\/span><\/a><\/p>\n Office\/Direct:\u00a0(858) 264-6500<\/span><\/p>\n Email:\u00a0<\/span>info@equinet.us<\/span><\/a><\/p>\n\n